TY - JOUR
T1 - Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice
AU - Stromnes, Ingunn M.
AU - Blattman, Joseph N.
AU - Tan, Xiaoxia
AU - Jeevanjee, Sara
AU - Gu, Hua
AU - Greenberg, Philip D.
PY - 2010/10/1
Y1 - 2010/10/1
N2 - The clinical use of adoptive immunotherapy with tumor-reactive T cells to treat established cancers is limited in part by the poor in vivo survival and function of the transferred T cells. Although administration of exogenous cytokines such as IL-2 can promote T cell survival, such strategies have many nonspecific activities and are often associated with toxicity. We show here that abrogating expression of Casitas B-lineage lymphoma b (Cbl-b), a negative regulator of lymphocyte activation, in tumor-reactive CD8+ T cells expanded ex vivo increased the efficacy of adoptive immunotherapy of disseminated leukemia in mice. Mechanistically, Cbl-b abrogation bypassed the requirement for exogenous IL-2 administration for tumor eradication in vivo. In addition, CD8+ T cells lacking Cbl-b demonstrated a lower threshold for activation, better survival following target recognition and stimulation, and enhanced proliferative responses as a result of both IL-2 - dependent and - independent pathways. Importantly, siRNA knockdown of Cbl-b in human CD8 +CD28- effector T cell clones similarly restored IL-2 production and proliferation following target recognition independent of exogenous IL-2, enhanced IFN-γ production, and increased target avidity. Thus, abrogating Cbl-b expression in effector T cells may improve the efficacy of adoptive therapy of some human malignancies.
AB - The clinical use of adoptive immunotherapy with tumor-reactive T cells to treat established cancers is limited in part by the poor in vivo survival and function of the transferred T cells. Although administration of exogenous cytokines such as IL-2 can promote T cell survival, such strategies have many nonspecific activities and are often associated with toxicity. We show here that abrogating expression of Casitas B-lineage lymphoma b (Cbl-b), a negative regulator of lymphocyte activation, in tumor-reactive CD8+ T cells expanded ex vivo increased the efficacy of adoptive immunotherapy of disseminated leukemia in mice. Mechanistically, Cbl-b abrogation bypassed the requirement for exogenous IL-2 administration for tumor eradication in vivo. In addition, CD8+ T cells lacking Cbl-b demonstrated a lower threshold for activation, better survival following target recognition and stimulation, and enhanced proliferative responses as a result of both IL-2 - dependent and - independent pathways. Importantly, siRNA knockdown of Cbl-b in human CD8 +CD28- effector T cell clones similarly restored IL-2 production and proliferation following target recognition independent of exogenous IL-2, enhanced IFN-γ production, and increased target avidity. Thus, abrogating Cbl-b expression in effector T cells may improve the efficacy of adoptive therapy of some human malignancies.
UR - http://www.scopus.com/inward/record.url?scp=77957830553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957830553&partnerID=8YFLogxK
U2 - 10.1172/JCI41991
DO - 10.1172/JCI41991
M3 - Article
C2 - 20890046
AN - SCOPUS:77957830553
SN - 0021-9738
VL - 120
SP - 3722
EP - 3734
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 10
ER -